|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0012655,
umls-concept:C0017262,
umls-concept:C0020792,
umls-concept:C0025914,
umls-concept:C0026809,
umls-concept:C0036341,
umls-concept:C0073393,
umls-concept:C0087111,
umls-concept:C0185117,
umls-concept:C0205314,
umls-concept:C0314603,
umls-concept:C0679622,
umls-concept:C0871261,
umls-concept:C0936012,
umls-concept:C1138555,
umls-concept:C1292724,
umls-concept:C1332838,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2911684,
umls-concept:C2911692
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-1-27
|
|
pubmed:abstractText |
Pharmacogenomic approaches based on genomewide sets of single nucleotide polymorphisms (SNPs) are now feasible and offer the potential to uncover variants that influence drug response.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1873-2402
|
|
pubmed:author |
pubmed-author:ArinamiTadaoT,
pubmed-author:HashimotoRyotaR,
pubmed-author:HondaHiroyukiH,
pubmed-author:IkedaMasashiM,
pubmed-author:IwataNakaoN,
pubmed-author:KinoshitaYokoY,
pubmed-author:KogaMinoriM,
pubmed-author:MouriAkihiroA,
pubmed-author:NabeshimaToshitakaT,
pubmed-author:NakamuraJunJ,
pubmed-author:O'DonovanMichael CMC,
pubmed-author:OkochiTomoT,
pubmed-author:OwenMichael JMJ,
pubmed-author:OzakiNorioN,
pubmed-author:TakedaMasatoshiM,
pubmed-author:TomitaYasuyukiY,
pubmed-author:WilliamsHywel JHJ,
pubmed-author:YamanouchiYoshioY,
pubmed-author:YoshimuraReijiR
|
|
pubmed:copyrightInfo |
Copyright 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
67
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
263-9
|
|
pubmed:meshHeading |
pubmed-meshheading:19850283-Animals,
pubmed-meshheading:19850283-Antipsychotic Agents,
pubmed-meshheading:19850283-Case-Control Studies,
pubmed-meshheading:19850283-Databases, Genetic,
pubmed-meshheading:19850283-Gene Frequency,
pubmed-meshheading:19850283-Genetic Predisposition to Disease,
pubmed-meshheading:19850283-Genome-Wide Association Study,
pubmed-meshheading:19850283-Genotype,
pubmed-meshheading:19850283-Humans,
pubmed-meshheading:19850283-Mice,
pubmed-meshheading:19850283-Oligonucleotide Array Sequence Analysis,
pubmed-meshheading:19850283-Pharmacogenetics,
pubmed-meshheading:19850283-Polymorphism, Single Nucleotide,
pubmed-meshheading:19850283-Prefrontal Cortex,
pubmed-meshheading:19850283-Psychiatric Status Rating Scales,
pubmed-meshheading:19850283-Risperidone,
pubmed-meshheading:19850283-Schizophrenia
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Identification of novel candidate genes for treatment response to risperidone and susceptibility for schizophrenia: integrated analysis among pharmacogenomics, mouse expression, and genetic case-control association approaches.
|
|
pubmed:affiliation |
MRC, Centre for Neuropsychiatric Genetics and Genomics, Department of Psychological Medicine and Neurology, School of Medicine, Cardiff University, Cardiff, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
